Dong Wei, Chief Operating Officer
Professional Overview
Dong Wei is an experienced biotechnology executive with a track record of driving innovation and operational excellence. As the Chief Operating Officer at Treos Bio and Co-Founder of Codone Biotechnology, he leverages his deep industry expertise and leadership capabilities to guide the strategic and day-to-day operations of these organizations.
Experience Summary
Current Roles
Chief Operating Officer, Treos Bio (2017-Present)
- Oversees the operational and administrative functions of Treos Bio, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies.
- Spearheads the implementation of efficient processes and systems to support the company's growth and ensure the successful advancement of its pipeline.
- Collaborates closely with the executive team to define and execute the company's strategic vision, contributing to its industry-leading position.
Co-Founder, Codone Biotechnology (2023-Present)
- Co-founded Codone Biotechnology, a start-up dedicated to developing cutting-edge gene editing technologies for therapeutic applications.
- Responsible for building the company's operational infrastructure, securing funding, and assembling a talented team of industry experts.
- Leads the strategic direction and day-to-day management of Codone Biotechnology to drive its mission of revolutionizing gene-based therapies.
Career Progression
CEO, EdiGene Inc. (2018-2023)
- Served as the Chief Executive Officer of EdiGene, a leading gene editing company, guiding the organization through a period of rapid growth and technological advancements.
- Spearheaded the development and clinical advancement of EdiGene's gene editing pipeline, positioning the company as a pioneer in the field.
- Secured significant funding and partnerships, further strengthening EdiGene's market position and enabling the expansion of its R&D capabilities.
Global Development Team Leader (Immunology), Shire (2016-2017)
- Played a pivotal role in the immunology division of Shire, leading the global development of innovative therapies.
- Drove the successful advancement of key pipeline assets through clinical trials, contributing to the company's growth and market leadership.
- Fostered cross-functional collaboration and implemented effective project management strategies to optimize drug development timelines.
Senior Roles, Baxalta, Johnson & Johnson, and Janssen Alzheimer Immunotherapy (2011-2016)
- Held senior leadership positions in program management, business operations, and project management at leading pharmaceutical companies.
- Demonstrated expertise in translating strategic objectives into operational excellence, driving the successful execution of complex, high-impact initiatives.
- Contributed to the advancement of therapeutic pipelines and the implementation of innovative business strategies.
Academic Background
Dong Wei holds a Ph.D. in Microbiology and Immunology from Michigan State University, where he conducted groundbreaking research in the field of carcinogenesis. He also completed postdoctoral fellowships at CHIRON CORPORATION (now part of Novartis) and Michigan State University, further expanding his scientific expertise.
Areas of Expertise
- Biotechnology and pharmaceutical operations management
- Gene editing and immunotherapy drug development
- Strategic planning and execution
- Cross-functional team leadership and collaboration
- Project and portfolio management
- Business development and partnership negotiations
Professional Impact
- Spearheaded the growth and technological advancements of EdiGene, positioning the company as a leader in the gene editing field.
- Drove the successful development and clinical advancement of innovative cancer immunotherapies at Treos Bio, contributing to the company's industry-leading position.
- Co-founded Codone Biotechnology, a start-up dedicated to developing transformative gene editing technologies for therapeutic applications.
- Demonstrated a proven track record of driving operational excellence, project management, and business development in the biotechnology and pharmaceutical industries.
Conclusion
Dong Wei's extensive experience and proven track record in the biotechnology industry make him a valuable asset to organizations seeking to drive innovation, operational efficiency, and strategic growth. His expertise in gene editing, immunotherapy, and pharmaceutical operations, combined with his strong leadership and collaborative skills, position him as a strategic and results-oriented executive poised to make a significant impact in the ever-evolving biotechnology landscape.
